Executive Order 12372 Review

Applications are not subject to the review requirements of Executive Order 12372, entitled Intergovernmental Review of Federal Programs.

Public Health System Reporting Requirement

This program is not subject to the Public Health System Reporting Requirements.

Catalog of Federal Domestic Assistance Number

The Catalog of Federal Domestic Assistance number is 93.262.

Other Requirements

Human Subjects

The applicant must comply with the Department of Health and Human Services Regulations, 45 CFR part 46, regarding the protection of human subjects. Assurances must be provided to demonstrate that the project will be subject to initial and continuing review by an appropriate institutional review committee. The applicant will be responsible for providing assurance in accordance with the appropriate guidelines and form provided in the application kit.

Women and Racial and Ethnic Minorities

It is the policy of the CDC to ensure that women and racial and ethnic groups will be included in CDC supported research projects involving human subjects, whenever feasible and appropriate. Racial and ethnic groups are those defined in OMB Directive No. 15 and include American Indian, Alaskan Native, Asian, Pacific Islander, Black and Hispanic. Applicants shall ensure that women and racial and ethnic minority populations are appropriately represented in applications for research involving human subjects. Where clear and compelling rationale exist that inclusion is not feasible, this situation must be explained as part of the application. In conducting the review of applications for scientific merit, review groups will evaluate proposed plans for inclusion of minorities and both sexes as part of the scientific assessment and assigned score. This policy does not apply to research studies when the investigator cannot control the race, ethnicity and/or sex of subjects. Further guidance to this policy is contained in the Federal Register, Vol. 60, No. 179, Friday, September 15, 1995, pages 47947–47951.

Application Submission and Deadlines

A. Preapplication Letter of Intent

Although not a prerequisite of application, a non-binding letter of intent-to-apply is requested from potential applicants. The letter should be submitted to the Grants Management Officer (whose address is reflected in section B, ''Applications''). It should be postmarked no later than March 14, 1997. The letter should identify the announcement number, name of principal investigator, and specify the priority area to be addressed by the proposed project. The letter of intent does not influence review or funding decisions, but it will enable CDC to plan the review more efficiently, and will ensure that each applicant receives timely and relevant information prior to application submission.

B. Applications

Applicants should use Form PHS–398 (OMB Number 0925–0001) and adhere to the ERRATA Instruction Sheet for Form PHS–398 contained in the grant application kit. Please submit an original and five copies on or before May 14, 1997 to: Ron Van Duyne, Grants Management Officer, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, (CDC), 255 East Paces Ferry Road, NE., Room 321, MS-E13, Atlanta, GA 30305.

C. Deadlines

1. Applications shall be considered as meeting a deadline if they are either:

A. Received at the above address on or before the deadline date, or

B. Sent on or before the deadline date to the above address, and received in time for the review process. Applicants should request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be accepted as proof of timely mailings.

2. Applications which do not meet the criteria above are considered late applications and will be returned to the applicant.

Where To Obtain Additional Information

To receive additional written information call (404) 332–4561. You will be asked your name, address, and telephone number and will need to refer to Announcement 722. You will receive a complete program description, information on application procedures, and application forms. In addition, this announcement is also available through the CDC Home Page on the Internet. The address for the CDC Home Page is http://www.cdc.gov. If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from Georgia Jang, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., MS–E13, Atlanta, GA 30305, telephone (404) 842–6796; fax: 404–842–6513; internet: glj2@cdc.gov. Programmatic technical assistance may be obtained from Roy M. Fleming, Sc.D., Associate Director for Grants, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, NE., Building 1, Room 3053, MS–D30, Atlanta, GA 30333, telephone 404–639–3343; fax: 404–639–4616; internet: rmf2@cdc.gov.

Please Refer to Announcement Number 722 When Requesting Information and Submitting an Application.

Potential applicants may obtain a copy of ''Healthy People 2000'' (Full Report, Stock No. 017–001–00474–0) or ''Healthy People 2000'' (Summary Report, Stock No. 017–001–00473–1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325, telephone (202) 512–1800.

Dated: February 11, 1997.

Diane D. Porter,

Acting Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–3909 Filed 2–14–97; 8:45 am]

BILLING CODE 4163–19–P

Food and Drug Administration

Advisory Committees; Tentative Schedule of Meetings for 1997

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 1997. At the request of the Commissioner of Food and Drugs (the Commissioner), the Institute of Medicine (the IOM) conducted a study of the use of FDA's advisory committees. The IOM recommended that the agency publish an annual tentative schedule of its meetings in the Federal Register. In response to that recommendation, FDA is publishing its

annual tentative schedule of meetings for 1997.

FOR FURTHER INFORMATION CONTACT: Donna M. Combs, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4820.

SUPPLEMENTARY INFORMATION: The IOM, at the request of the Commissioner, undertook a study of the use of FDA's advisory committees. In its final report, the IOM recommended that FDA adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the Federal Register. FDA has implemented this recommendation. A tentative schedule of forthcoming meetings will be published annually in the Federal Register. The annual publication of tentatively scheduled advisory committee meetings will provide both advisory committee members and the public with the opportunity, in advance, to schedule attendance at FDA's upcoming advisory committee meetings. The schedule is tentative and amendments to this notice will not be published in the Federal Register. FDA will, however, publish a Federal Register notice at least 15 days in advance of each upcoming advisory committee meeting, announcing the meeting (21 CFR 14.20).

The following list announces FDA's tentatively scheduled advisory committee meetings for 1997:

Committee name	Dates of meetings	Hotline code
OFFICE OF THE COMMISSIONER		
Science Board to the Food and Drug Administration	March 13 May 14 November 5	12603
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH		
Allergenic Products Advisory Committee	April 17–18 September 29–30	12388
Biological Response Modifiers Advisory Committee	January 30 May 6–7 July 24–25 October 16–17	12388
Blood Products Advisory Committee	March 13–14 June 19–20 September 18–19 December 11–12	12388
Transmissible Spongiform Encephalopathies Advisory Committee	To be announced (presently, committee is unstaffed)	12388
Vaccines and Related Biological Products Advisory Committee	January 30 March 14 April 10–11 July 10–11 October 27–28	12388
CENTER FOR DRUG EVALUATION AND RESEARCH		
Advisory Committee for Pharmaceutical Science	May 7–8 August 20–21	12539
Advisory Committee for Reproductive Health Drugs	June 5–6	12537
Anesthetic and Life Support Drugs Advisory Committee	March 27–28 May 22–23 September 17–18	12529
Anti-Infective Drugs Advisory Committee	January 22 (joint meeting with Nonprescription Drugs Advisory Committee) March 5–7 July 24–25 November 20–21	12530
Antiviral Drugs Advisory Committee	February 21 April 24–25 September 11–12	12531
Arthritis Advisory Committee	February 4–5 March 18–19 May 6–7 July 22–23 November 4–5	12532
Cardiovascular and Renal Drugs Advisory Committee	January 23 (joint meeting with Nonprescription Drugs Advisory Committee) February 27–28 June 26–27 October 23–24	12533
Dermatologic and Ophthalmic Drugs Advisory Committee	April 17–18 July 17–18 September 15–16 November 13–14	12534
Drug Abuse Advisory Committee	February 10–11 June 9–10 November 20–21	12535
Endocrinologic and Metabolic Drugs Advisory Committee	February 20–21	12536

Committee name	Dates of meetings	Hotline code
	March 25–26 April 14–15 May 13–14 July 10–11 August 21–22 September 22–23 November 20–21	
Gastrointestinal Drugs Advisory Committee	September 18–19 December 2	12538
Medical Imaging Drugs Advisory Committee	March 6–7	12540
Nonprescription Drugs Advisory Committee	January 22 (joint meeting with Anti-Infective Drugs Advisory Committee) January 23 (joint meeting with Cardiovascular and Renal Drugs Advisory Committee) March 17–19 May 13–14 (with representation from Endocrinologic and Metabolic Drugs Advisory Committee)	12541
Oncologic Drugs Advisory Committee	March 7 May 1–2 June 23–24	12542
Peripheral and Central Nervous System Drugs Advisory Committee	June 26–27	12543
Psychopharmacologic Drugs Advisory Committee	July 14–16 August 4–5 November 5–7	12544
Pulmonary-Allergy Drugs Advisory Committee	April 10–11	12545
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION		
Food Advisory Committee	March 20–21 May 21–23 July 30–31 and August 1 September 24–26 November 19–21	10564
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH		
Device Good Manufacturing Practice Advisory Committee	No meetings planned	12398
Medical Devices Advisory Committee		
Anesthesiology and Respiratory Therapy Devices Panel	June 6 September 5 November 21	12624
Circulatory System Devices Panel	June 16 November 17	12625
Clinical Chemistry and Clinical Toxicology Devices Panel	March 20-21 May 8 July 24–25 September 25–26	12514
Dental Products Panel	February 12 May 21–23 July 14–16 November 3–5	12518
Ear, Nose, and Throat Devices Panel	May 20–21 October 22–23 December 11–12	12522
Gastroenterology-Urology Devices Panel	January 16 May 1–2 August 7–8 November 6–7	12523
General and Plastic Surgery Devices Panel	May 5–6 August 4–5 November 3–4	12519
General Hospital and Personal Use Devices Panel	June 2–3 September 15–16 November 13–14	12520
Hematology and Pathology Devices Panel	June 26–27 September 4–5 November 20–21	12515
Immunology Devices Panel	June 13 September 19 December 5	12516
Microbiology Devices Panel	June 19–20 September 11–12	12517
Neurological Devices Panel	March 14 June 27	12513
Obstetrics-Gynecology Devices Panel	April 14–15	12524

Committee name	Dates of meetings	Hotline code
Ophthalmic Devices Panel	July 14–15 October 6–7 January 13–14 March 27–28 July 10–11 October 20–21	12396
Orthopedic and Rehabilitation Devices Panel	March 6–7 June 9–10 October 15–16	12521
Radiological Devices Panel	February 24 May 12 August 18 November 17	12526
National Mammography Quality Assurance Advisory Committee	January 13–15 August 18–20 November 3–5	12397
Technical Electronic Product Radiation Safety Standards Committee	April 8–9	12399
CENTER FOR VETERINARY MEDICINE		
Veterinary Medicine Advisory Committee	May 13–14	12546
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH		
Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee)	September 15–16	12560
Science Advisory Board to the National Center for Toxicological Research	June 4–5	12559

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

Dated: February 7, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–3821 Filed 2–14–97; 8:45 am]

BILLING CODE 4160–01–F

Health Care Financing Administration

HCFA–P–15A

Agency Information Collection Activities: Submission for OMB Review; Comment Request

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, has submitted to the Office of Management and Budget (OMB) the following proposal for the collection of information. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

HCFA–P–15A *Type of Information Collection Request:* Extension of currently approved collection; *Title of Information Collection:* Medicare Current Beneficiary Survey Supplement-Round 18; *Form No.:* HCFA–′P–15A; *Use:* The Office of the Actuary, HCFA, conducts the Medicare Current Beneficiary Survey (MCBS) through personal interviews of a random sample of Medicare beneficiaries. When sampled persons are found to reside in a long-term care facility, interviewers use a version of the questionnaire which is specially designed to obtain data about the beneficiary's health care from knowledgeable staff members. We are preparing to convert the facility interview from a hard—copy questionnaire to a Computer Assisted Personal Interviewing (CAPI) format, beginning in May, 1997. CAPI, which we are currently using in the community interviews, increases the accuracy of the interview process by automating skip patterns, customizing questions, creating computed variables such as a time line of residence history, and automatically checking completeness and consistency of responses. Concurrently, we are modifying some of the questions we currently use in the facility interview to make them more comparable to those in other surveys, particularly the Medical Expenditure Panel Survey (MEPS). These modifications are responsive to the President's initiative toward consistency and integration among surveys; *Frequency:* Annually; *Affected Public:; Number of Respondents:* 1,900;